Patents by Inventor Oliver Schroeder

Oliver Schroeder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240139855
    Abstract: An apparatus of a setting welding device for an auxiliary joining part with a head and a shaft, includes a linear drive fastenable at the setting device and including an element nest at a movable end, in which an auxiliary joining part is releasably receivable from a transfer unit. The element nest is movable by the linear drive in a first direction. The element nest is supported in a floating manner, and is positionable via a mechanical stop alignment in abutment with an electrode punch in the joining direction below the electrode punch. And/or the element nest is connected with the linear drive via a mechanical direction-changing coupling component so that the element nest is movable by the linear drive in a second direction so that the auxiliary joining part is positionable at the joining location, wherein the second direction is not parallel to the first direction.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Dennis Schröder, Bernd Haesler, Kilian Doedtmann, Stefan Rehling, Sergej Hartwig-Biglau, Wilhelm Westermann, Oliver Schienstock
  • Patent number: 11965263
    Abstract: The invention relates to a substrate holding and locking system for chemical and/or electrolytic surface treatment of a substrate in a process fluid and a corresponding method. The system comprises a first element, a second element, a reduced pressure holding unit and a magnetic locking unit. The first element and the second element are configured to hold the substrate between each other. The reduced pressure holding unit comprises a pump to reduce an interior pressure inside the substrate holding and locking system below atmospheric pressure. The magnetic locking unit is configured to lock the first element and the second element with each other. The magnetic locking unit comprises a magnet control and at least a magnet. The magnet is arranged at one of the first element and the second element. The magnet control is configured to control a magnetic force between the first element and the second element.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: April 23, 2024
    Assignee: SEMSYSCO GMBH
    Inventors: Herbert Ötzlinger, Oliver Knoll, Raoul Schröder, Markus Gersdorff, Thomas Wirnsberger, Georg Hofer, Andreas Gleissner
  • Patent number: 11938522
    Abstract: The invention relates to a module for chemically processing a substrate, a method for chemically processing a substrate and a use of a module for chemically processing a substrate and in particular a large substrate. The module for chemically processing a substrate comprises: an immersion chamber, a spray unit, and a motion unit (14). The immersion chamber is configured to receive a first liquid and the substrate, so that the substrate is immersed in the liquid. The spray unit comprises a plurality of spray nozzles, which are configured to spray a second liquid within the immersion chamber. The motion unit is configured to provide a relative motion between the substrate and the spray unit.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: March 26, 2024
    Assignee: SEMSYSCO GMBH
    Inventors: Andreas Gleissner, Herbert Ötzlinger, Raoul Schröder, Oliver Knoll
  • Publication number: 20230111363
    Abstract: The present invention relates to antibodies that specifically bind human monocarboxylate transporter 1 (MCT1) (“anti-human MCT1 antibodies”), compositions comprising such anti-human MCT1 antibodies, and methods of using such anti-human MCT1 antibodies.
    Type: Application
    Filed: September 14, 2022
    Publication date: April 13, 2023
    Inventors: Frank Charles Dorsey, Joseph Benjamin Granger, Kira Vladimirovna Rubtsova, Oliver Schroeder, Wei Wang
  • Patent number: 11492395
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: November 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20220110537
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: 11267882
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • Patent number: 11242383
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 8, 2022
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20210147530
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 20, 2021
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: 10919959
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20200199212
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 25, 2020
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20200199213
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 25, 2020
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Publication number: 20190233508
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Application
    Filed: March 24, 2017
    Publication date: August 1, 2019
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • Patent number: 9394362
    Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 19, 2016
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
  • Publication number: 20150294239
    Abstract: A first itinerary comprising a first plurality of first location elements associated with locations to be visited during a trip, each first location element comprising first duration information, first arrival date information, and first departure date information, is maintained. A second itinerary comprising a plurality of transport elements associated with transportation to be used during the trip and a second plurality of second location elements, each second location element associated with a corresponding first location element, each second location element comprising second duration information, second arrival date information, and second departure date information is maintained. Modification information indicating that a duration specified in a selected first location element has been altered is received. A first duration, first arrival date information, or first departure date information in a first location element is adjusted based on the modification information.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 15, 2015
    Inventors: Madelein Constanza ARAYA HERNANDEZ, Manuel AGUILA YANEZ, Benjamin Sebastian Ariel DIAZ CABALLERO, Michael Harald HAASE, Johannes HEBBELMANN, Danny Enrique PERICH LARA, Fabian Leonardo PERICH LARA, Oliver SCHROEDER, David STAUFFER, Justus Fritz ZEPPENFELD
  • Publication number: 20150266954
    Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 24, 2015
    Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder